Rapid Plasma Thawing Device (RPTD)
| Reference number | |
| Coordinator | Antrad Medical AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | November 2017 - December 2017 |
| Status | Completed |
Important results from the project
Outlining of businessplan for the development and commercialisation of next generation blood plasma thawing device for clinical use. In scope was identification and verification of technical improvement areas in relation to existing thawing device prototype. Also in scope was a market feasibility study for better understanding of the marketpotential. With the new businessplan, technical know-how and market data our potential for realisation of the development and commercialisation of next generation device has increased substantially.
Expected long term effects
The company will and has already begun to adjust the company structure and organization. Together with identified partners that are already established in the market the Antrad company will be able to significantly shorten lead times for product development and commercialisation. Within the technology area we have identified a number of areas for improvement which potentially will lead to faster and more robust instruments that can be manufactured at a lower cost. Within the market feasibility area we have additional confirmation for the need of a new device not only in blood banks.
Approach and implementation
Within the technology area the company has together with external resources identified a number technical improvements. Some of them have already been verified in tests. The market feasibility study was mainly conducted with internal resources analysing published marketdata. This material has been complemented and verified in talks with potential partners and customers.